Search
Ecamsule
go.drugbank.com/drugs/DB09534ApprovedEcamsule has been approved for use in the U.S. since 2006, but only at a specific concentration and only in a few products manufactured by L'Oreal. … Ecamsule is an organic compound which is added to many sunscreens to filter out UVA rays. It is a benzylidene camphor derivative, many of which are known for their excellent photostability.
Mixtures: Kiehls Since 1851 Dermatologist Solutions Ultra Light Daily UV Defense Tone Up SPF 50 PA Plus Plus Plus Plus Antipollution, Hydraphase UvCategories: Compounds used in a research, industrial, or household settingDibotermin alfa
go.drugbank.com/drugs/DB11639ApprovedInvestigationalDibotermin alfa is a recombinant human bone morphogenetic protein-2 (rhBMP-2) derived from a recombinant Chinese Hamster Ovary (CHO) cell line [FDA Label]. … Dibotermin alfa was approved by the EMA in 2002 as Inductos for implantation matrix. In 2004, it was approved by the FDA and is marketed as Infuse.
Etryptamine
go.drugbank.com/drugs/DB01546ApprovedIllicitWithdrawnIn the 1960's, alpha-ethyltryptamine (αET), a non hydrazine reversible monoamine oxidase inhibitor, was developed in the United States by the Upjohn chemical company for use as an antidepressant. αET was … In 1993, the US Drug Enforcement Administration added αET to Schedule I of its Schedules of Controlled Substances, after an increasing incidence of its use as a recreational drug in the 1980's.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesSamidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigational, and a longer half-life, making it an attractive candidate for oral dosing. … [A235638, A235643] Samidorphan is a novel opioid antagonist structurally related to [naltrexone], with a higher affinity for opioid receptors, more potent μ-opioid receptor antagonism, higher oral bioavailability
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesGalactose
go.drugbank.com/drugs/DB11735ApprovedInvestigationalWithdrawnAs a naturally occurring sugar, it may be found in a number dairy products. Even then, however, it is not generally used as a sweetener considering it is only about 30% as sweet as sucrose. … Regardless, although it is predominantly used as a pathway to generate glucose fuel for the human body, galactose is involved as an ingredient in some commonly used vaccines and non-prescription products
Mixtures: Levovist - Pws IV (4g Granules /vial)Vecuronium
go.drugbank.com/drugs/DB01339ApprovedInvestigationalIts lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or … A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium.
Categories: P-glycoprotein substratesProducts: BROCURIX 10 MG POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCIÓN INYECTABLE, BROMURO DE VECURONIO 4 MG/VIAL POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLEZanubrutinib
go.drugbank.com/drugs/DB15035ApprovedInvestigationalL10166] which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug. … [A187967] BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and proliferation of malignant B cells.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexMedium-chain triglycerides
go.drugbank.com/drugs/DB13959ApprovedInvestigationalMedium-chain triglycerides (MCTs) are triglycerides made up of a glycerol backbone and three fatty acids with an aliphatic tail of six to 12 carbon atoms. … [A246688] MCTs are used in parenteral nutrition therapy: they serve as a source of calories and essential fatty acids in conditions associated with malnutrition and malabsorption.[L41340]
Mixtures: CELEPID MCT-LCT 20% W/V, CELEPID MCT-LCT 20% W/VVarenicline
go.drugbank.com/drugs/DB01273ApprovedInvestigationalA full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S. … The FDA said it is keeping the black box in place at least until the results of the trial are announced.
Ranibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigationalRanibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology … BYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada.